Geode Capital Management LLC Raises Stock Holdings in Lifecore Biomedical, Inc. (NASDAQ:LFCR)

Geode Capital Management LLC grew its holdings in Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 14.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 685,746 shares of the company’s stock after buying an additional 88,061 shares during the quarter. Geode Capital Management LLC owned 1.85% of Lifecore Biomedical worth $5,097,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in LFCR. DCF Advisers LLC boosted its stake in Lifecore Biomedical by 87.2% during the 4th quarter. DCF Advisers LLC now owns 539,989 shares of the company’s stock worth $4,012,000 after purchasing an additional 251,511 shares during the last quarter. 272 Capital LP lifted its stake in shares of Lifecore Biomedical by 511.1% in the third quarter. 272 Capital LP now owns 143,480 shares of the company’s stock worth $707,000 after buying an additional 120,002 shares in the last quarter. Bank of New York Mellon Corp boosted its position in Lifecore Biomedical by 71.9% during the fourth quarter. Bank of New York Mellon Corp now owns 80,572 shares of the company’s stock worth $599,000 after acquiring an additional 33,690 shares during the last quarter. Rhumbline Advisers boosted its position in Lifecore Biomedical by 125.9% during the fourth quarter. Rhumbline Advisers now owns 55,723 shares of the company’s stock worth $414,000 after acquiring an additional 31,056 shares during the last quarter. Finally, State Street Corp grew its stake in Lifecore Biomedical by 10.2% during the 3rd quarter. State Street Corp now owns 334,360 shares of the company’s stock valued at $1,648,000 after acquiring an additional 30,916 shares in the last quarter. 83.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Stephens reaffirmed an “equal weight” rating and issued a $6.00 target price on shares of Lifecore Biomedical in a research note on Friday, January 3rd.

Lifecore Biomedical Stock Performance

NASDAQ LFCR opened at $6.38 on Friday. The company has a fifty day moving average of $6.19 and a two-hundred day moving average of $6.37. The company has a debt-to-equity ratio of 9.21, a current ratio of 2.32 and a quick ratio of 1.21. Lifecore Biomedical, Inc. has a 1 year low of $3.68 and a 1 year high of $7.99. The company has a market capitalization of $236.22 million, a PE ratio of -11.39 and a beta of 0.80.

Lifecore Biomedical (NASDAQ:LFCR) last posted its quarterly earnings data on Thursday, April 3rd. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.05). Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. The company had revenue of $35.15 million for the quarter, compared to analysts’ expectations of $33.23 million. As a group, analysts expect that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current year.

Lifecore Biomedical Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.